Reply to the letter to the editor by Wuyts et al.??Burning down DEFECT11?

Shaffer, Lisa G.

doi:10.1002/1096-8628(20010515)100:4<333::aid-ajmg1272>3.0.co;2-i

Cited by 6 publications

(5 citation statements)

References 18 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…I am not alone in pursuing this lofty goal as others have also taken up the gauntlet to rid of offensive terminology in the medical literature [Biesecker and Pilz, 2001; Sheffer, 2001; Wuyts et al, 2001].…”

Section: To the Editormentioning

confidence: 99%

In vitro studies of platelet adhesion, activation, and protein adsorption on curcumin‐eluting biodegradable stent materials

Pan

Shao

Tang

et al. 2007

J Biomedical Materials Res

View full text Add to dashboard Cite

A major complication of coronary stenting is in-stent restenosis (ISR) due to thrombus formation. We hypothesized that locally released curcumin from coronary stent surface would inhibit ISR due to thrombus formation because of antithrombosis of curcumin. In the present work, curcumin-eluting polylactic acid-co-glycolic acid (PLGA) films were fabricated and their properties in vitro were investigated. The in vitro platelet adhesion and activation, as well as protein adsorption on curcumin-loading PLGA films were investigated to evaluate the blood compatibility of curcumin-eluting films. The structure of curcumin-eluting PLGA film and control was examined by Fourier transform infrared spectroscopy and X-ray photoelectron spectroscopy indicating that the peaks of curcumin did not shift in curcumin-eluting films. The results of contact angle and surface free energy indicated that loading curcumin in PLGA would make PLGA become more hydrophilic, which contributed to the increase of polar fraction of surface free energy. With the increase of curcumin in films, platelets adhering to the curcumin-eluting films decreased significantly. The number of activation platelets decreased after incorporating curcumin in PLGA films. Loading curcumin in PLGA film can markedly reduce the fibrinogen adsorption. All results indicated that incorporating curcumin in PLGA film can improve the blood compatibility of PLGA films. It can be used to fabricate drug-eluting stent to prevent thrombosis formation.

show abstract

Section: To the Editormentioning

confidence: 99%

In vitro studies of platelet adhesion, activation, and protein adsorption on curcumin‐eluting biodegradable stent materials

Pan

Shao

Tang

et al. 2007

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…Potocki–Shaffer syndrome (PSS) (MIM # 601224) is a contiguous gene deletion syndrome (CGDS) (previously referred to as DEFECT 11 [1,2]) caused by the haploinsufficiency of genes located in 11p11.2 [3–5]. Clinical findings include biparietal foramina, multiple exostoses, dysmorphic features, and mental retardation [3,5–8].…”

mentioning

confidence: 99%

Familial case of Potocki–Shaffer syndrome associated with microdeletion of EXT2 and ALX4

Hall

Shaffer

et al. 2001

Clinical Genetics

View full text Add to dashboard Cite

Multiple exostosis, biparietal foramina, minor craniofacial abnormalities, and mental retardation are characteristic of the syndrome associated with a proximal deletion of 11p (MIM # 601224), which has been shown to be a true contiguous gene deletion syndrome. The presence of multiple exostosis is associated with deletion of the EXT2 gene. Similarly, the presence of biparietal foramina has been shown to be associated with the deletion of ALX4 located proximally to EXT2. Specific genes related to mental retardation and craniofacial abnormalities, however, have yet to be identified. We report on a family with a microdeletion of 11(pll.2p11.2) with multiple exostosis and biparietal foramina without mental retardation or craniofacial abnormalities. Our results suggest that genes related to mental retardation and craniofacial development must be located outside of the D11S1785-D11S1385 region.

show abstract

“…In her thoughtful reply to Wuyts et al concerning the debate over naming syndromes, Dr. Shafer lists six reasons in favor of using eponyms for describing syndromes [Carey, 2001;Shaffer, 2001;Wuyts et al, 2001]. The sixth reason was``eponyms are usually not offensive to patients.''…”

Section: To the Editormentioning

confidence: 99%